PDUFA dates May 2016: FDA calendar and catalysts.
0 PDUFA dates fell in May 2016. The FDA calendar also recorded 5 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in May 2016
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
May 2016: other FDA decisions and filings
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| May 4, 2016 | VELCADE® (bortezomib) | RDY | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| May 10, 2016 | Ameluz (aminolevulinic acid hydrochloride) | BFRI | FDA approval | — | Approved | openFDA Drugs@FDA |
| May 10, 2016 | Ztlido (lidocaine) | SCLX | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| May 27, 2016 | Zinbryta (daclizumab) | BIIB | FDA approval | — | Approved | openFDA Drugs@FDA |
| May 27, 2016 | AUSTEDO (deutetrabenazine) | TEVA | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
May 2016: dated readouts
No events in this view.
Questions
What PDUFA dates are in May 2016?
0 PDUFA dates fell in May 2016. The FDA calendar also recorded 5 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.